PF-8380 inhibits rat autotaxin with an IC50 of 1.16 nM when tested with the FS-3 substrate. The efficacy of PF-8380 is sustained when the enzyme, derived from fetal fibroblasts, is combined with lysophosphatidyl choline (LPC) as the substrate. In human whole blood incubated with PF-8380 for 2 hours, autotaxin inhibition occurs with an IC50 of 101 nM[1]. Autotaxin (ATX), an enzyme with lysophospholipase D (lysoPLD) activity, converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). Treatment of GL261 and U87-MG cells with 1 μM PF-8380 prior to 4 Gy irradiation leads to reduced clonogenic survival, lowered migration (33% in GL261; P=0.002 and 17.9% in U87-MG; P=0.012), decreased invasion (35.6% in GL261; P=0.0037 and 31.8% in U87-MG; P=0.002), and reduced radiation-induced Akt phosphorylation[2].
体内研究
The pharmacokinetic properties of PF-8380 are assessed following an intravenous dose of 1 mg/kg and oral doses ranging from 1 to 100 mg/kg over a 24-hour period. PF-8380 exhibits a mean clearance rate of 31 mL/min/kg, a steady-state distribution volume of 3.2 L/kg, and an effective half-life of 1.2 hours. Its oral bioavailability is moderate, varying between 43 and 83%. Plasma concentrations rise with increasing single oral doses; however, the maximum concentration (Cmax) increases roughly proportionally with doses from 1 to 10 mg/kg and less than proportionally from 10 to 100 mg/kg. Drug exposure, as estimated by the area under the curve (AUC), is approximately proportional to the dose and remains linear up to 100 mg/kg. Levels of plasma C16:0, C18:0, and C20:0 LPA are measured immediately after collection. The most significant reduction in LPA levels occurs at the 3 mg/kg dose within 0.5 hours, with all LPA levels returning to or surpassing baseline by 24 hours[1].
Treatment with 10 mg/kg PF-8380 modestly increases tumor-associated vascularity by 20% (P=0.497). However, administering PF-8380 45 minutes before a 4 Gy irradiation reduces vascularity by nearly 48% compared to control (P=0.031), and by 65% relative to mice that underwent radiation alone (P=0.011)[2].
体外研究
PF-8380 inhibits rat autotaxin with an IC50 of 1.16 nM when tested with the FS-3 substrate. The efficacy of PF-8380 is sustained when the enzyme, derived from fetal fibroblasts, is combined with lysophosphatidyl choline (LPC) as the substrate. In human whole blood incubated with PF-8380 for 2 hours, autotaxin inhibition occurs with an IC50 of 101 nM[1].
Autotaxin (ATX), an enzyme with lysophospholipase D (lysoPLD) activity, converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). Treatment of GL261 and U87-MG cells with 1 μM PF-8380 prior to 4 Gy irradiation leads to reduced clonogenic survival, lowered migration (33% in GL261; P=0.002 and 17.9% in U87-MG; P=0.012), decreased invasion (35.6% in GL261; P=0.0037 and 31.8% in U87-MG; P=0.002), and reduced radiation-induced Akt phosphorylation[2].
PF-8380 细胞实验
Cell Line
Concentration
Treated Time
Description
References
SCC cells
1 μM
Inhibit ATX activity and evaluate its effect on cell proliferation
Commun Biol. 2024 Jan 5;7(1):26.
EHEB cells
16 μM and 32 μM
24 h
PF-8380 exerts therapeutic potential by inhibiting CLL cell survival and cell cycle, enhancing apoptosis and chemosensitivity.
Cell Mol Biol Lett. 2024 Dec 27;29(1):159.
MEC-1 cells
16 μM and 32 μM
24 h
PF-8380 exerts therapeutic potential by inhibiting CLL cell survival and cell cycle, enhancing apoptosis and chemosensitivity.
Cell Mol Biol Lett. 2024 Dec 27;29(1):159.
LR-MSCs
1 µM
30 min
PF-8380 significantly reduced the migration rates of FOXF1-silenced LR-MSCs, with levels comparable to scrambled control siRNA transfected LR-MSCs
To assess the effect of PF8380 on macrophage inflammatory response, results showed that PF8380 treatment significantly reduced the TNF-α/IL-10 ratio, indicating attenuated inflammatory response.
J Mol Cell Cardiol. 2020 Dec;149:95-114.
PF-8380 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
SCC tumor model
Oral
30 mg/kg
Twice daily, starting from day +10
Evaluate the effect of PF-8380 on SCC tumor growth, finding that PF-8380 initially prevents tumor growth but then the tumor burden progressively reaches that of untreated mice
Commun Biol. 2024 Jan 5;7(1):26.
Mice
PRG-1-/- mice and PRG-1R346T mice
Intraperitoneal injection
30 mg/kg
Single dose, lasting 3 hours
PF-8380 reduced cortical hyperexcitability and restored behavioral phenotypes in PRG-1-/- and PRG-1R346T mice by inhibiting ATX activity.
Mol Psychiatry. 2018 Aug;23(8):1699-1710
Mouse
GL261 heterotopic tumor model
Intraperitoneal injection
10 mg/kg
Once daily for five consecutive days
Delayed tumor growth, reduced tumor vascularity
Front Oncol. 2013 Sep 17;3:236.
Mice
Myocardial infarction model
Intraperitoneal injection
10 mg/kg
Twice daily for 7 days
To evaluate the effect of PF8380 on post-myocardial infarction inflammatory response, results showed that PF8380 significantly reduced the inflammatory response, improved cardiac functional recovery, reduced scar size and enhanced angiogenesis.
搜索
